Tirzepatide is an investigational peptide designed to mimic the action of incretin hormones, such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). By activating both GIP and GLP-1 receptors, Tirzepatide promotes the release of insulin in response to glucose levels while also inhibiting the production of glucagon, leading to improved glucose control. This dual-action mechanism lowers blood sugar levels and reduces the amount of glucose produced by the liver. Additionally, Tirzepatide has been found to slow down gastric emptying, extending the feeling of fullness and potentially contributing to weight loss. These combined effects make Tirzepatide a promising candidate in the management of type 2 diabetes and obesity.